AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00292201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
Study NCT00292201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
Study NCT01088295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT00964483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
Study NCT00964483 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
Study NCT00964483 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Intervention
Description: The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure.
Study NCT00661726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (USAN, INN)
Description: Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
Study NCT04244695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
Study NCT04244695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
Study NCT04244695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone Oral
Description: To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
Study NCT01248572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Softec HD IOL
Description: Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
Study NCT03529617 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: Plasma, urine, BAL and ascitic fluid sample collection.
Study NCT02085044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-Used Supplement Food administration
Study NCT02085044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-Used Supplement Food administration
Study NCT01846299 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
Study NCT01846299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
Study NCT01321255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC
Description: FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
Study NCT01321255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Separately drugs, simvastatin, aspirin and ramipril
Description: Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
Study NCT02463708 — intervention group
Intervention type: BEHAVIORAL
Intervention: BHL COTP
Description: The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
Study NCT04290247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound imaging for fracture diagnosis before conventional X-ray
Study NCT02065843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mulungu
Description: 500 mg/single dose/1 hour before dental surgery
Study NCT02065843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg/single dose/1 hour before dental surgery
Study NCT02065843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Passiflora incarnata
Description: 100 mg/single dose/1 hour before dental surgery
Study NCT02065843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: 15 mg/single dose/1 hour before dental surgery
Study NCT04502693 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo was administered intramuscularly.
Study NCT04502693 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-1
Description: Lot 1 of the MenABCWY vaccine was administered intramuscularly.
Study NCT04502693 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2
Description: Lot 2 of the MenABCWY vaccine was administered intramuscularly.
Study NCT04502693 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-3
Description: Lot 3 of the MenABCWY vaccine was administered intramuscularly.
Study NCT00816530 — intervention group
Intervention type: DEVICE
Intervention: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
Description: After density > 50% is confirmed by routine digital screening mammography, ABUS will be performed.
Study NCT01893164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simple decompression
Description: decompression of the ulnar nerve
Study NCT01893164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior subcutaneous transposition
Description: transposition of the ulnar nerve into subcutaneous bed
Study NCT01893164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior intramuscular transposition
Description: transposition of the ulnar nerve into muscular tissue
Study NCT04352712 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling
Study NCT03385005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.
Description: The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.
Study NCT03350581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAM 3D map group
Description: Radiofrequency catheter ablation using the 3D map which is constructed by FAM alone.
Study NCT03350581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FAM-CT 3D map group
Description: Radiofrequency catheter ablation using the 3D map which is constructed by the integration of the FAM with CT or MRI.
Study NCT05185193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency
Description: Radiofrequency of 9.50v, 218.5mA and 2.076W is applied once a day for 30 minutes, a total of 3 times
Study NCT05185193 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The appearance is the same as the medical device for clinical trials, and when applied, the sound and the amount of light visible from the outside are designed to be the same as the medical device for clinical trials. The external light was the same, and only the high frequency that stimulates the dermis was blocked. The sham device was applied once a day for 30 minutes, a total of 3 times.
Study NCT04178486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis with amnesia suggestions
Description: Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
Study NCT04178486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis with cognitive rehearsal suggestions
Description: Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
Study NCT04178486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis with memory substitution suggestions
Description: Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
Study NCT04178486 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hypnosis with induction only
Description: Participants received only hypnotic induction.
Study NCT00896571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestogene (BAY86-5016)
Description: 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
Study NCT02485197 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 7 continuous days of aerobic training
Description: For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
Study NCT03342183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation).
Study NCT03342183 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Arm
Description: Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
Study NCT01284829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG-PET scan
Study NCT03504657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon angioplasty
Description: Angioplasty with a drug-coated angioplasty
Study NCT03504657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenting angioplasty
Description: Angioplasty with a stenting
Study NCT01369095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C\&D)
Study NCT01369095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C\&D)
Study NCT01369095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836 Placebo
Description: Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)
Study NCT01369095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836 Placebo
Description: Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)
Study NCT04113512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jalaneti
Description: Sterilised and lukewarm isotonic salt water using neti pot was poured into one nostril, so that it leaves through the other. The procedure is then repeated on the other side, and the nose is dried by bending forward and by rapid yoga breathing
Study NCT00212758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutropin AQ
Description: Nutropin AQ
Study NCT01369095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
Study NCT01369095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
Study NCT00845845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3-acid ethyl esters (Lovaza)
Description: 4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
Study NCT00845845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo with dietary counseling for 24 weeks.
Study NCT01369095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
Study NCT01369095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
Study NCT03201835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNL-THC:CBD soft gelatin capsule
Description: 3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
Study NCT03201835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: spray X 4 actuations
Study NCT03201835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD hard capsule dose 1
Description: 1 hard capsule containing 10 mg CBD
Study NCT03381625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-010
Description: Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.
Study NCT03381625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
Study NCT04262791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Actigraphy Device
Description: Wrist Actigraphy Device
Study NCT04262791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep Headband
Description: Sleep Headband
Study NCT00187850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PP
Description: Partial pulpotomy
Study NCT00187850 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: DPC
Description: Direct pulp capping
Study NCT03201835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-PNL-THC:CBD soft gelatin capsule
Description: 2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
Study NCT03201835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD hard capsule dose 2
Description: 1 hard capsule containing 100 mg CBD
Study NCT03728790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
Study NCT00884871 — intervention group
Intervention type: PROCEDURE
Intervention: LapBand
Description: Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
Study NCT01581645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobilaser
Description: Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
Study NCT01452828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA single infusion
Description: Single IV infusion, 200 mg daily for 7 days
Study NCT01452828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Two separate infusions of 200 mg
Study NCT01452828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Single IV infusion, 200 mg daily for 7 days
Study NCT03026400 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transumbilical incision
Description: While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
Study NCT03026400 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subumbilical incision
Description: Considered here as the ''control'' intervention.
Study NCT00689234 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: diaphragm plication 6 months after inclusion
Description: thoracotomy
Study NCT00689234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diaphragm plication at time of inclusion
Description: thoracotomy
Study NCT04770662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Administered Questionnaires:~* Dutch version of Children's Yale-Brown Obsessive Compulsive Scale (CYBOCS, Goodman W.K. e.a.)~* Dutch version of Eating Disorder Inventory-3 (EDI-3, David M. Garner)~* General Questionnaire: demografic , scholar and social information and child psychiatric history~* Dutch version of the Child Behavior Checklist (CBCL, T.M. Achenbach)~* Anorectic Behavior Observation Scale (ABOS, Vandereycken W., Universitair Centrum Kortenberg, 1992)
Study NCT03078660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: The smartphone Application generates a shopping list for participants, based on a low caloric diet (energy requirements minus 500 kcals), taking into consideration the Dietary Guidelines for Americans' recommendations and also considering the available budget for each shopping event and the weekly discounts from major supermarkets.
Study NCT03078660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Nutritional Counseling
Description: Participants will have a face-to-face counseling session with a registered dietitian, who will provide recommendations for a low caloric diet (energy requirements minus 500 kcals) using the food group sheets from the Dietary Guidelines for Americans.
Study NCT02052531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028
Description: Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
Study NCT01582958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
Study NCT01582958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham omt
Description: Hands are placed on subjects the same as omt arm but no omt is provided.
Study NCT02052531 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Participants received topical Vehicle twice daily for 4 weeks
Study NCT03304548 — intervention group
Intervention type: OTHER
Intervention: Telephone concept elicitation interview
Description: All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
Study NCT02978430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer-assisted GDFT
Description: Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
Study NCT02978430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
Study NCT05670249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suboccipital decompressive craniectomy
Description: extensive bilateral suboccipital decompressive craniectomy with duraplasty
Study NCT04483297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK1320 MS
Description: AK1320 MS + Local Autologous Bone + Posterior Fixation. Ascending Dose.